← Other lipid agents × lipids

TrialAmerican heart journal2009

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

Syed M Mohiuddin et al.PubMed ↗Publisher ↗

  • ABT-335 + simvastatin 20no clear effectHigher HDL-C increased, no range given, lower TGs decreased, no range given, lower LDL-C decreased, no range given.No ranges given.
  • ABT-335 + simvastatin 40no clear effectHigher HDL-C increased, no range given, lower TGs decreased, no range given, lower LDL-C decreased, no range given.No ranges given.

What the trial testedas reported · 657 people · 2009

No range given

Reported higher HDL-C increased, no range given

+17.8percentage points

ABT-335 + simvastatin 20 vs simvastatin 20

As reported

difference 17.8 %, no interval

No range given

Reported lower TGs decreased, no range given

−37.4percentage points

ABT-335 + simvastatin 20 vs simvastatin 20

As reported

difference −37.4 %, no interval

No range given

Reported lower LDL-C decreased, no range given

−24.0percentage points

ABT-335 + simvastatin 20 vs ABT-335

As reported

difference −24.0 %, no interval

No range given

Reported higher HDL-C increased, no range given

+18.9percentage points

ABT-335 + simvastatin 40 vs simvastatin 40

As reported

difference 18.9 %, no interval

+2 more in the walkthrough ↓

Who was studied, and how

657people with dyslipidemia, in this paper

The trial randomly assignedassigned by chance

ABT-335 + simvastatin 20
simvastatin 20

Reported higher HDL-C increased, no range given+17.8

Reported lower TGs decreased, no range given−37.4

randomised

The trial randomly assignedassigned by chance

ABT-335 + simvastatin 20
ABT-335

Reported lower LDL-C decreased, no range given−24.0

randomised

the abstract, start to end

HDL-C increased 17.8% versus 7.2% and TGs decreased -37.4% versus -14.2% (ABT-335 + simvastatin 20 vs simvastatin 20); LDL-C decreased -24.0% versus -4.0% (ABT-335 + …

HDL-C increased 18.9% versus 8.5% and TGs decreased -42.7% versus -22.4% (ABT-335 + simvastatin 40 vs simvastatin 40); LDL-C decreased -25.3% versus -4.0% (ABT-335 + …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HDL-C increasedABT-335 + simvastatin 20 vs simvastatin 20
17.8
TGs decreasedABT-335 + simvastatin 20 vs simvastatin 20
−37.4
LDL-C decreasedABT-335 + simvastatin 20 vs ABT-335
−24.0
HDL-C increasedABT-335 + simvastatin 40 vs simvastatin 40
18.9
TGs decreasedABT-335 + simvastatin 40 vs simvastatin 40
−42.7
LDL-C decreasedABT-335 + simvastatin 40 vs ABT-335
−25.3
StatinsOther lipid agentsLipids
1 / 4

26 papers cite it

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01974297194 enrolled2013
Full record →Abstract, authors, funding and every citing paper · PMID 19081418